ArticleEye (London, England)2026
Clinical characteristics and outcomes of intraocular inflammation following intravitreal faricimab for neovascular age-related macular degeneration: a single-centre retrospective study.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the clinical characteristics and outcomes of intraocular inflammation (IOI) following intravitreal faricimab injection in a real-world setting.
methodsThis retrospective single-centre cohort study evaluated eyes developing IOI following intravitreal faricimab injection. Clinical characteristics, SUN-graded inflammatory features, intraocular pressure (IOP) changes, and time to resolution were analysed.
resultsA total of 14 eyes from 13 patients developed IOI following intravitreal faricimab injection, corresponding to an incidence of 0.13% per injection. All eyes developed anterior chamber inflammation, with two-thirds also demonstrating associated vitritis. Fifty percent (7/14 eyes) presented with an IOP > 21 mmHg. Overall, IOP increased from baseline in 11/14 eyes (79%), with 5 eyes (36%) demonstrating a clinically significant rise of ≥10 mmHg. The severity of acute anterior uveitis and vitritis correlated positively with time to resolution, whereas the presence of hypertensive uveitis did not significantly affect resolution time. The mean time to resolution was approximately two months. DISCUSSION: This study provides a comprehensive characterisation of post-faricimab IOI, including detailed SUN-graded phenotyping, IOP outcomes, and recurrent inflammatory episodes. Greater inflammatory severity was associated with prolonged resolution time, while hypertensive features did not appear to influence inflammatory recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.